Displaying drugs 10701 - 10725 of 12610 in total
Diclofop-methyl
Herbicide for control of wild oat & foxtails in cereal crops.
Experimental
Matched Description: … Herbicide for control of wild oat & foxtails in cereal crops. …
GFH-925
GFH-925 is an irreversibly covalent inhibitor of KRAS G12C.
Investigational
Matched Description: … GFH-925 is an irreversibly covalent inhibitor of KRAS G12C. …
Sar9, Met (O2)11-Substance P
Sar9, Met (O2)11-Substance P is a neurokinin-1 receptor agonist. It is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.
Investigational
Matched Description: … the body, including in the airways of humans and many other species. ... It is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout …
MK-4721
MK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients with all stages of prostate, pancreatic and bladder cancers.
Investigational
Matched Description: … patients with all stages of prostate, pancreatic and bladder cancers. ... Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of …
BBM-H803
BBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed and manufactured by Belief BioMed. It consists of an adeno-associated virus vector containing an expression cassette of the human Factor VIII transgene.
Investigational
Matched Description: … It consists of an adeno-associated virus vector containing an expression cassette of the human Factor …
MB07811
MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing. MB07811 combines a novel thyroid hormone receptor agonist with the...
Investigational
Matched Description: … MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower ... The combination of selectivity for the beta form of the receptor, liver targeting and other structural ... is designed to provide significant efficacy while avoiding side effects associated with activation of …
Tunicamycin
Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P HexNAc-1-P family of enzymes. One member of this family is the enzyme GlcNAc phosphotransferase (GPT), which catalyzes the transfer of N-acetylglucosamine-1-phosphate from UDP-N-acetylglucosamine to dolichol phosphate in the first step of glycoprotein synthesis in eukaryotes. Tunicamycin blocks...
Experimental
Matched Description: … HexNAc-1-P family of enzymes. ... of glycoprotein synthesis in eukaryotes. ... Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P …
Tesevatinib
Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.
Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). Tesevatinib inhibits the EGF, HER2, and VEGF RTKs,...
Investigational
Matched Description: … Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer ... demonstrated potent inhibition of tumor growth and causes tumor regression. ... Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases …
αAβ–Gas6
αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is...
Experimental
Matched Description: … It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody ... [A253203,A253208] αAβ–Gas6 is a phagocyte inducer of Aβ,[A253203] which is the main component of the ... fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is a ligand …
Setrusumab
Setrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density).
Investigational
Matched Description: … Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density). ... Setrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing …
Vofatamab
Vofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma).
Investigational
Matched Description: … (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma). ... Vofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab …
Imalumab
Imalumab is under investigation in clinical trial NCT02540356 (Phase 1/2a Two-arm Dose-escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer).
Investigational
Matched Description: … BAX69 in Subjects With Malignant Ascites of Ovarian Cancer). ... Imalumab is under investigation in clinical trial NCT02540356 (Phase 1/2a Two-arm Dose-escalation Study of …
Milciclib Maleate
Milciclib Maleate is under investigation in clinical trial NCT01301391 (Study of Oral PHA-848125AC in Patients With Malignant Thymoma Previously Treated With Multiple Lines of Chemotherapy).
Investigational
Matched Description: … Patients With Malignant Thymoma Previously Treated With Multiple Lines of Chemotherapy). ... Milciclib Maleate is under investigation in clinical trial NCT01301391 (Study of Oral PHA-848125AC in …
Pegcantratinib
Pegcantratinib is under investigation in clinical trial NCT03448081 (Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene).
Investigational
Matched Description: … SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene). ... Pegcantratinib is under investigation in clinical trial NCT03448081 (Safety, Tolerability and Efficacy of …
HSK-3486
HSK-3486 is under investigation in clinical trial NCT04620031 (A Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Mechanical Ventilation).
Investigational
Matched Description: … Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Mechanical Ventilation). ... HSK-3486 is under investigation in clinical trial NCT04620031 (A Study Evaluating Sedation of Intravenous …
Letaplimab
Letaplimab is under investigation in clinical trial NCT04485052 (Efficacy and Safety Evaluation of IBI188 in Combination With Azacitidine in Treatment of Patients With Acute Myeloid Leukemia).
Investigational
Matched Description: … in Combination With Azacitidine in Treatment of Patients With Acute Myeloid Leukemia). ... Letaplimab is under investigation in clinical trial NCT04485052 (Efficacy and Safety Evaluation of IBI188 …
MPI-674
MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. It is...
Investigational
Matched Description: … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and ... It is developed for the treatment of several serious women’s health conditions including endometrial …
Pipequaline
Pipequaline is an anticonflict & anticonvulsant quinoline derivative. It is an anxiolytic drug that was never marketed. It presents a unique chemical structure that does not follow the structural properties of other drugs of its class. Pipequaline has a similar pharmacological profile to the reported for the benzodiazepines. However, it...
Experimental
Matched Description: … of its class. ... It presents a unique chemical structure that does not follow the structural properties of other drugs ... However, it presents a significant set of anxiolytic properties with a very little sedative, amnestic …
LNP-nCoVsaRNA Vaccine
LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly...
Investigational
Matched Description: … of the vaccine. ... LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV ... As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity …
iCo-007
iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).
Investigational
Matched Description: … known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of ... various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related …
DNB-001
DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma. In preclinical animal models, DNB-001 has demonstrated potent IOP- lowering effects as well as neuroprotective effects on the optic nerve.
Investigational
Matched Description: … for the treatment of glaucoma. ... DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed …
IC41
IC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C. The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell epitopes and the synthetic adjuvant poly-L-arginine.
Investigational
Matched Description: … It is being devloped by Intercell AG for the treatment of hepatitis C. ... The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell …
Ad-CEA vaccine
Ad-CEA vaccine is a cancer immunotherapy composed of carcinoembryonic antigen (CEA). Ad-CEA vaccine is under investigation in clinical trial NCT03050814 (Standard of Care Alone or in Combination With Ad-cea Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004).
Investigational
Matched Description: … Ad-CEA vaccine is a cancer immunotherapy composed of carcinoembryonic antigen (CEA). ... Ad-CEA vaccine is under investigation in clinical trial NCT03050814 (Standard of Care Alone or in Combination …
RGX-181
RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1) gene. Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
Investigational
Matched Description: … RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble ... Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid …
Elsubrutinib
Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State).
Investigational
Matched Description: … Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib …
Displaying drugs 10701 - 10725 of 12610 in total